Changing epidemiology of Hepatitis A: Time for vaccination in childhood

Journal of Travel Medicine

Volumn 7, Issue 3, 2000, Pages 142-148

  Jelinek, Tomas ^a   Nothdurft, Hans D ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS VACCINE;

ACTIVE IMMUNIZATION; ENDEMIC DISEASE; HEPATITIS A; HIGH RISK POPULATION; HUMAN; INCUBATION TIME; MORBIDITY; REVIEW; RISK FACTOR; SYMPTOM; VACCINATION; VIRUS TRANSMISSION;

EID: 0033918816     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.2310/7060.2000.00046     Document Type: Review

References (91)

1. Strader D, Seeff L. Immunization of viral hepatitis. Curr Opin Gastroenterol 1996; 12:224-230.
2. Hadler S. Global impact of hepatitis A virus infection; changing patterns. In; Lemon S, Margolis H, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991:4-20.
3. Lemon S, Thomas D. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336:196-204.
4. Anonymous. Hepatitis surveillance. Atlanta: Centers tor Disease Control and Prevention, 1995.
5. Lemon S, Jansen R, Brown E. Genetic, antigenic and biological differences between strains of hepatitis A virus. Vaccine 1992; 10(Suppl 1):S40.
6. Terrault N, Wright TL. Viral hepatitis A through G. In: Feldmann M, Scharschmidt B, Sleisenger M, eds. Gastrointestinal and liver disease. 6th Ed. Vol. 2. Philadelphia: WB Saunders, 1998:1123-1129.
7. Tong M, El-Farra N, Grew M. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. J Infect Dis 1995; 171(Suppl 1):S15-18.
8. Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 1992; 10(Suppl 1):S15-17.
9. Gust I. Clinical features. In: Feinstone S, ed. Hepatitis A. Boca Raton, FL: CRC Press, 1988:145-162.
10. Seeff L. Diagnosis, therapy and prognosis of viral hepatitis. In: Zakim D, Boyer T, eds. Hepatology: a textbook of liver disease. 2nd Ed. Philadelphia: WB Saunders, 1990:958-1025.
11. Koff R. Seroepidemiology of hepatitis A in the United States. J Infect Dis 1995; 171(Suppl):S19-23.
12. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327:453-457.
13. Debray D, Cullufi P, Devictor D, et al. Liver failure in children with hepatitis A. Hepatology 1997; 26:1018-1022.
14. Melnick J. History and epidemiology of hepatitis A virus. J Infect Dis 1995; 171(Suppl 1):S2-8.
15. Melnick J. Properties and classifications of hepatitis A virus. Vaccine 1992; 10(Suppl 1):S24.
16. Xu Z, Hu S. Epidemiology of hepatitis A. Monogr Virol 1992; 19:119-125.
17. Shapiro C, Margolis H. Worldwide epidemiology of hepatitis A infection. J Hepatol 1993; 18(Suppl 2):S11.
18. Bassily S, Hyams K, el Ghorab N, et al. Acute sporadic hepatitis in adults living in Cairo, Egypt. Am J Trop Med Hyg 1986; 35:1040-1044.
19. Frösner G. Hepatitis A virus. In: Belshe R, ed. Textbook of human virology. St. Louis: Mosby, 1990:498-516.
20. Hadler S, Erben J, Francis D, et al. Risk factors for hepatitis A in day-care centers. J Infect Dis 1982; 145:255-261.
21. Hadler S, Webster H, Erben J, et al. Hepatitis A in day-care centers. A community-wide assessment. N Engl J Med 1980; 302:1222-1227.
22. Hadler S, Erben J, Matthews D, et al. Effect of immunoglobulm on hepatitis A in day-care centers. JAMA 1983; 249:48-53.
23. Benenson M, Takafuji E, Bancroft W et al. A military community outbreak of hepatitis type A related to transmission in a child care facility. Am J Epidemiol 1980; 112:471-481.
24. Conzelmann Auer C, Ackermann Liebrich U, Herzog C, Bachlin A. Hepatitis A outbreak in a kindergarten. Schweiz Med Wochenschr 1992; 122:1559-1566.
25. Smith PF, Grabau JC, Werzberger A, et al. The role of young children in a community-wide outbreak of hepatitis A. Epidemiol Infect 1997; 118:243-252.
26. Perez-Trallero E, Cilla G, Urbieta M, et al. Falling incidence and prevalence of hepatitis A in northern Spain. Scand J Infect Dis 1994; 26:133-136.
27. Bolumar F, Giner-Duran R, Hernandez-Aguado I, et al. Epidemiology of hepatitis A in Valencia, Spain: public health implications. J Viral Hepatol 1995; 2:145-149.
28. Papaevangelou G, Totos G, Roumeliotou A, Safary A. Brief report: hepatitis A vaccination in Greek military recruits. J Med Virol 1993; 40:1-4.
29. Poovorawan Y, Theamboonlers A, Vimolkej T, Chongsrisawat V. Prevalence of infection with hepatitis A virus among primary-school children in Bangkok, Thailand. Ann Trop Med Parasitol 1997; 91:119-120.
30. Agosti M, Velez A, Pizarro N, et al. Epidemiologica de la hepatitis en ninos. Bol Venez Infect 1997;7(Suppl 1):39.
31. Lemon S. Type A viral hepatitis: new developments in an old disease. N Engl J Med 1985; 313:1059.
32. Lednar W, Lemon S, Kirkpatrick J, et al. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985; 122:226-233.
33. Romero R, Lavine J. Viral hepatitis in children. Semin Liver Dis 1994; 14:289-302.
34. Bromberg K, Newhall D, Peter G. Hepatitis A and meningoencephalitis. JAMA 1982; 247:815.
35. Shrier L, Karpen S, McEvoy C. Acute pancreatitis associated with acute hepatitis A in a young child. J Pediatr 1995; 126:57-59.
36. Meriem C, Pousse H, Radhouane M, et al. Hepatitie et glomerulonephrite aigue. Arch Pediatr 1995;2:91-92.
37. Breningstall G, Belani K. Acute transverse myelitis and brain-stem encephalitis associated with hepatitis A infection. Pediatr Neurol 1995; 12:169-171.
38. Nachbaur K, Konig P, Rumpelt H, et al. Acute renal failure complicating non-fulminant hepatitis A. Clin Nephrol 1996; 45:398-400.
39. Zacarias J, Brinck P, Cordero J, Velasco M. Etiologies of fulminant hepatitis in pediatric patients in Santiago, Chile. Pediatr Infect Dis 1987; 6:686-687.
40. Fonseca J, Ferreira L, Brasii L, et al. Fulminant hepatitis: etiological and histopathological aspects in the western Amazon region, Brazil. J Hepatol 1992; 17(Suppl 1):S40.
41. Friedland J, Zuckerman M, Kala U, Parbhoo K. Fulminant hepatitis in children: report of 12 cases. Ann Trop Paediatr 1991; 11:207-211.
42. Rakela J, Redeker A, Edwards V, et al. Hepatitis A virus infection in fulminant hepatitis and chronic active hepatitis. Gastroenterol 1978; 74:879-882.
43. Mathiesen L, Skinhoj P, Hardt F, et al. Epidemiology and clinical characteristics of acute hepatitis types A, B, and non-A non-B. Scand J Gastroenterol 1979; 14:849-856.
44. Acharya S, Dasarathy S, Kumer T, et al. Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology 1996; 23:1448-1455.
45. Anonymous. Hepatitis surveillance report. Atlanta: Centers of Disease Control and Prevention, 1990.
46. Steffen R, Kane M, Shapiro C, et al. Epidemiology and prevention of hepatitis A in travelers. JAMA 1994; 272:885-889.
47. Arora N, Nanda S, Gulati S, et al. Acute viral hepatitis types E, A and B singly and in combination in acute liver failure in children in North India. J Med Virol 1996; 48:215-221.
48. Tandon A, Bhujwala R, Tandon B. Severe hepatitis due to HAV infection in adults. Hepatol 1996;23(Suppl 1):S79.
49. Weiland O, Niklasson B, Berg R, et al. Clinical and subclinical hepatitis A occurring after immunoglobulin prophylaxis among Swedish UN soldiers in Sinai. Scand J Gastroenterol 1981; 16:967-972.
50. Widell A, Zhang Y, Andersson-Gare B, Hammarstrom L. At least three hepatitis C virus strains implicated in Swedish and Danish patients with intravenous immunoglobulin-associated hepatitis C. Transfusion 1997; 37:313-320.
51. Andre F, Hepburn A, D'Hondt E. Inactivated candidate vaccines for hepatitis A. Prog Med Virol 1990; 37:72-95.
52. Andre F, D'Hondt E, Delem A, Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 1992; 10(Suppl 1):S160-168.
53. Lemon SM, Shapiro CN. The value of immunization against hepatitis A. Infect Agents Dis 1994; 3:38-49.
54. Green M, Cohen D, Lerman Y, et al. A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine. Isr J Med Sci 1994; 30:485-488.
55. Clemens R, Safary A, Hepburn A, et al. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; 171(Suppl 1):S44-49.
56. Innis B, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271:1328-1334.
57. McMahon BJ, Williams J, Bulkow L, et al. Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults. J Infect Dis 1995; 171(Suppl 1):S44-49.
58. Shouval D, Ashur Y, Adler R, et al. Safety, to erability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin. J Hepatol 1993; 18(Suppl 2):S32-37.
59. Westblom T, Gudipati S, DeRousse C, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule. J Infect Dis 1994; 169:996-1001.
60. Widermann G, Ambrosch F, Kollaristch H, et al. Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers. Vaccine 1990; 8:581-584.
61. Anstegui J, Morales JL, Dal Re R, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine in children 2 to 5 years old. Infect 1995; 23:334-338.
62. Jilg W, Bittner R, Bock H, et al. Vaccination against hepatitis A: comparison of different short-term immunization schedules. Vaccine 1992; 10(Suppl 1):S126-128.
63. Muller R, Bock H, Clemens R, Jilg W. Aktive Immunisierung gegen Hepatitis A. Vergleich verschiedener Impfschemata. Dtsch Med Wochenschr 1993; 118:1101-1104.
64. Balcarek K, Bagley M, Pass R, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 1995; 171(Suppl 1):S70-72.
65. Sandman L, Davidson M, Krugman S. Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals. J Infect Dis 1995; 171(Suppl 1):S50-52.
66. DeFraites R, Feighner B, Binn L, et al. Immunization of US soldiers with a two-dose primary series of inactivated hepatitis A vaccine: early immune response, persistence of antibody, and response to a third dose at 1 year. J Infect Dis 1995; 171(Suppl 1):S61-69.
67. Findor J, Canero Valesco M, Mutti J, Safary A. Response to hepatitis A vaccine in children after a single dose with a booster administration 6 months later. J Travel Med 1996; 3:156-159.
68. Zuckerman J, Kirkpatrick C, Huang M. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A. J Travel Med 1998; 5:18-22.
69. Arya S. Protection of travelers against hepatitis A viral infection in developing countries. J Travel Med 1998;5:228-229.
70. Vidor E, Ratheau C, Briantais P, Vuillier D. Comparison of two immunization schedules with an inactivated hepatitis A vaccine (Avaxim). J Travel Med 1998;5:167-172.
71. Chan C, Lee S, Yu M, et al. Long-term follow-up of hepatitis A vaccination in children. Vaccine 1999; 17:369-372.
72. Mao J, Chen N, Huang H, et al. Development of live attenuated hepatitis A vaccine (H2-strain). Chin Med J Engl 1992; 105:189-193.
73. Mao J, Chai S, Xie R, et al. Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2-strain) in humans. Vaccine 1997; 15:944-947.
74. Ambrosch F, Andre F, Delem A, et al. Simultaneous vaccination against hepatitis A and B: results of a controlled study. Vaccine 1992; 10(Suppl 1):S142-145.
75. Ambrosch F, Widermann G, Andre F, et al. Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. J Med Virol 1994; 44:452-456.
76. Kallinowski B, Bock H, Clemens R, Theilmann L. Immunogenicity and reactogencity ofa combined hepatitis A/B candidate vaccine: first results. Liver 1996; 16:271-273.
77. Anonymous. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996; 45:1-30.
78. Anonymous. AAP develops guidelines for hepatitis A vaccine and immune globulin in children. American Academy of Pediatrics. Am Fam Physician 1997; 55:2535-2536.
79. Bader TF. Hepatitis A vaccine. Am J Gastroemerol 1997; 91:217-222.
80. Innis B, Snitbhan R, Hoke C, et al. The declining transmission of hepatitis A in Thailand. J Infect Dis 1991; 163:989-995.
81. Green MS, Tsur S, Slepon R. Sociodemographic factors and the declining prevalence of anti-hepatitis A antibodies in young adults in Israel: implications for the new hepatitis A vaccines. Int J Epidemiol 1992; 21:136-141.
82. Papaevangelou G. Epidemiology of hepatitis A in Mediterranean countries. Vaccine 1992; 10(Suppl 1):S63-66.
83. Abdool Karim SS, Coutsoudis A. Sero-epidemiology of hepatitis A in black South African children. S Afr Med J 1993; 83:748-750.
84. Sathar MA, Soni PN, Fernandes Costa FJ, et al. Racial differences in the seroprevalence of hepatitis A virus infection in Natal/KwaZulu, South Africa. J Med Virol 1994; 44:9-12.
85. Song E, Kew MC. The seroepidemiology of hepatitis A virus infection in South African Chinese people. J Viral Hepat 1994; 1:149-153.
86. Kalayanarooj S, Vaughn DW, Snitbhan R, Ariyasriwatana C. Age-specific prevalence of hepatitis A antibody in Thai children. Southeast Asian J Trop Med Public Health 1995; 26:709-711.
87. Queiroz DA, Cardoso DD, Martelli CM, et al. Risk factors and prevalence of antibodies against hepatitis A virus (HAV) in children from day-care centers, in Goiania, Brazil. Rev Inst Med Trop Sao Paulo 1995; 37:427-433.
88. Anonymous. Prevention of hepatitis A infections: guidelines for use of hepatitis A vaccine and immune globulin. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 1996; 98:1207-1215.
89. Strader DB, Seeff LB. New hepatitis A vaccines and their role in prevention. Drugs 1996; 51:359-366.
90. Margolis HS, Shapiro CN. Who should receive hepatitis A vaccine? Considerations for the development of an immunization strategy. Vaccine 1992; 10(Suppl 1):S85-87.
91. Hollinger F, Eickhoff T, Gershon A, et al. Discussion: who should receive hepatitis A vaccine? A strategy for controlling hepatitis A in the United States. J Infect Dis 1995; 171:73-77.